1. Home
  2. RFM vs KPTI Comparison

RFM vs KPTI Comparison

Compare RFM & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFM
  • KPTI
  • Stock Information
  • Founded
  • RFM 2020
  • KPTI 2008
  • Country
  • RFM United States
  • KPTI United States
  • Employees
  • RFM N/A
  • KPTI N/A
  • Industry
  • RFM Finance/Investors Services
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • RFM Finance
  • KPTI Health Care
  • Exchange
  • RFM Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • RFM 92.3M
  • KPTI 81.1M
  • IPO Year
  • RFM N/A
  • KPTI 2013
  • Fundamental
  • Price
  • RFM $15.70
  • KPTI $0.62
  • Analyst Decision
  • RFM
  • KPTI Strong Buy
  • Analyst Count
  • RFM 0
  • KPTI 4
  • Target Price
  • RFM N/A
  • KPTI $5.00
  • AVG Volume (30 Days)
  • RFM 20.7K
  • KPTI 679.6K
  • Earning Date
  • RFM 01-01-0001
  • KPTI 02-27-2025
  • Dividend Yield
  • RFM 9.74%
  • KPTI N/A
  • EPS Growth
  • RFM N/A
  • KPTI N/A
  • EPS
  • RFM N/A
  • KPTI N/A
  • Revenue
  • RFM N/A
  • KPTI $148,442,000.00
  • Revenue This Year
  • RFM N/A
  • KPTI $5.47
  • Revenue Next Year
  • RFM N/A
  • KPTI $6.33
  • P/E Ratio
  • RFM N/A
  • KPTI N/A
  • Revenue Growth
  • RFM N/A
  • KPTI 1.77
  • 52 Week Low
  • RFM $12.89
  • KPTI $0.58
  • 52 Week High
  • RFM $16.41
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • RFM 65.66
  • KPTI 41.95
  • Support Level
  • RFM $15.24
  • KPTI $0.60
  • Resistance Level
  • RFM $15.60
  • KPTI $0.69
  • Average True Range (ATR)
  • RFM 0.07
  • KPTI 0.05
  • MACD
  • RFM 0.05
  • KPTI -0.00
  • Stochastic Oscillator
  • RFM 99.98
  • KPTI 18.17

About RFM RiverNorth Flexible Municipal Income Fund Inc.

RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: